LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.05 2.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.97

Max

1.06

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	5.5M -32M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+418.63% upside

Turustatistika
By TradingEconomics
Turukapital	-13M 112M
Eelmine avamishind	-1.89
Eelmine sulgemishind	1.05

Uudiste sentiment

By Acuity

91%

5 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. nov 2025, 23:36 UTC

Kuumad aktsiad

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19. nov 2025, 22:13 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19. nov 2025, 21:55 UTC

Suurimad hinnamuutused turgudel

Amgen Lung Cancer Drug Gets Full Approval From FDA

19. nov 2025, 21:43 UTC

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19. nov 2025, 23:55 UTC

Market Talk

Gold Rises on Possible Investment Demand -- Market Talk

19. nov 2025, 23:54 UTC

Market Talk

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19. nov 2025, 23:47 UTC

Tulu

Lenovo Group 2Q EPS $2.52 >0992.HK

19. nov 2025, 23:46 UTC

Tulu

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19. nov 2025, 23:45 UTC

Tulu

Lenovo Group 2Q Rev $20.5B >0992.HK

19. nov 2025, 23:42 UTC

Market Talk

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19. nov 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

19. nov 2025, 23:41 UTC

Tulu

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19. nov 2025, 23:41 UTC

Tulu

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19. nov 2025, 23:40 UTC

Tulu

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19. nov 2025, 22:55 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19. nov 2025, 22:41 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19. nov 2025, 22:30 UTC

Omandamised, ülevõtmised, äriostud

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19. nov 2025, 22:30 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19. nov 2025, 22:30 UTC

Omandamised, ülevõtmised, äriostud

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19. nov 2025, 22:27 UTC

Omandamised, ülevõtmised, äriostud

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19. nov 2025, 22:08 UTC

Tulu

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19. nov 2025, 22:00 UTC

Tulu

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19. nov 2025, 21:58 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19. nov 2025, 21:52 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19. nov 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

19. nov 2025, 21:49 UTC

Market Talk

Tulu

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19. nov 2025, 21:38 UTC

Tulu

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19. nov 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Palo Alto Networks to Buy Chronosphere for $3.35B

19. nov 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19. nov 2025, 21:24 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

418.63% tõus

12 kuu keskmine prognoos

Keskmine 5.29 USD 418.63%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

5 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.